Ping An Biomedical Co., Ltd. - Class A Ordinary Shares (PASW)

HONG KONG, July 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (hereinafter referred to as “Ping An Biomedical”) announced that it has formally signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd. (hereinafter referred to as “Yuan Sheng Mei Yan”). Under the agreement, Yuan Sheng Mei Yan will serve as a channel development service provider for Ping An Biomedical. The two parties will engage in deep cooperation in the broader health and wellness services market, with a shared goal of achieving cumulative sales of RMB 500 million within three years.

HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that shareholders have approved all five resolutions at the company’s 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high‑vote Class B shares, a targeted share exchange with a major shareholder, and a large‑scale share consolidation.

ADM Endeavors (OTCQB: ADMQ), a diversified direct marketing and value-added manufacturing company, continues to build momentum as its wholly owned subsidiary Just Right Products, Inc., delivers consistent revenue growth, expands into new markets, and significantly scales its operational facility footprint.

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”).

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors.

Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter.